



## Palettra™

Where insight ignites innovation


Revolutionizing spatial biology –  
translating precious tissue into  
therapeutic advancement

# Introducing Palettra™

The spatial proteomics solution transforming every tissue into deep visual insights that fuel confident decisions and accelerate informed clinical advancement, backed by over a decade of expertise in MultiOmyx™, a cyclic immunofluorescence technology.


## Full-spectrum spatial context

Larger scan area up to 8.5 cm<sup>2</sup>, providing comprehensive coverage of formalin-fixed paraffin-embedded (FFPE) tissues




## Integrated with RNAscope™

Combines spatial analysis of proteins and RNA biomarkers





## Improves understanding of disease pathology at the tissue level



## Hyperplex technology

Power to analyze 60+ protein biomarkers in a single tissue section using advanced cyclic immunofluorescence






### AI-driven segmentation and cell phenotyping

Greater accuracy and reproducibility — deep-learning algorithms trained on 20 million single-cell annotations and extensively evaluated across tumor types

- A. AI-driven tissue segmentation
- B. AI-driven cell segmentation, including subcellular compartments
- C. AI-driven biomarker classification and cell phenotyping

### Advanced spatial analytics and bioinformatics

Aligned to your exact specification



Region segmentation    Proximity analysis    Nearest neighbors    Neighborhood composition    Intensity metrics

#### Cell-level outputs:

- Co-expressions
- Intensities
- Quality control (QC) metrics
- Morphology
- Location
- Distance to target cells\*

#### Slide-level outputs:

- Tissue areas
- Cell counts and densities for biomarkers and co-expressions
- Percent positivity and cell ratios\*
- Mean fluorescence intensity\*
- H-score\*
- Nearest neighbor distance and proximity\*

**Advanced analytics unlock salient spatial information that provides biological insight into the tumor microenvironment, enabling target validation, mechanism of action, unveiling complex biological processes, and precision medicine**

\*Configurable outputs.

**Off-the-shelf test menu** and **custom capability** to meet your specific needs


Panel	Markers	Cell types classified in TME
Immune (TIL) Panel 14 markers	CD3, CD4, CD8, FoxP3, CD20, CD68, CD56, CTLA4, PD1, PDL1, PanCK/SOX10, Ki67, GrzB, CD45RO	T cells, B cells, NK cells, and TAMs
TIL & Myeloid Panel 16 markers	CD3, CD4, CD8, FoxP3, CD20, CD68, CD163, CD11b, CD15, TIM3, LAG3, OX40, ICOS, PD1, PDL1, PanCK/SOX10	T cells, B cells, TAMs, and granulocytes
TME Panel 16 markers	CD3, CD4, CD8, FoxP3, CD11b, CD11c, CD31, CD68, CD163, HLADR, GrzB, FAP, PD1, PDL1, Ki67, PanCK	T cells, B cells, M1/M2 TAMs, CAFs, endothelial cells, dendritic cells, and tumor proliferation
TME/TLS Panel 33 markers	CD3, CD4, CD8, CD45RO, FoxP3, GrzB, CD11b, CD11c, CD14, CD15, CD20, CD21, CD23, CD31, CD38, CD56, CD68, CD163, CXCL13, PNAd, PD1, PDL1, TIM3, CTLA-4, TCF1/TCF7, DC-LAMP, FAP, HLA-ABC, HLA-DR, Ki67, SMA, PanCK/SOX10, TOX/TOX2	Quantity, distribution, and maturity of TLS, T cells, B cells, NK cells, TAMs, CAFs, and dendritic cells
Dendritic Cell Panel 15 markers	CD3, CD4, CD8, CD11c, CD14, CD40, CD68, CD123, CD141, CD163, HLA-DR, Clec9a, DC-SIGN, DC-LAMP, SOX10/PanCK	Dendritic cells, T cells, and TAMs
TIL/TAM & Vessel Panel 14 markers	CD3, CD4, CD8, FoxP3, GrzB, VISTA, CD68, CD163, CD206, CD31, LAG3, TIM3, PD1, PanCK/SOX10	T cells, TAMs, and vessels

These panels also differentiate functionally activated immune cells from suppressed immune cells

To learn more about NeoGenomics Pharma Services, visit us online at [NeoGenomics.com/Partners](https://www.neogenomics.com/Partners), call us at **866.776.5907, option 3**, or email us at [ContactPharma@NeoGenomics.com](mailto:ContactPharma@NeoGenomics.com).

NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and oncology data solutions. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service, sample-processing laboratory in Cambridge, England, United Kingdom.

### Cell phenotyping in non-small cell lung cancer (NSCLC) using TME panel



### Selected publications utilizing NeoGenomics' spatial services

- Al-Janabi H, et al. *J Immunother Cancer*. 2024;12(7):e009368.
- Altorki NK, et al. *Cell Rep Med*. 2024;5(3):101438.
- Bockorny B, et al. *Nat Med*. 2020;26(6):878-885.
- Hilton JF, et al. *Cancer Immunol Immunother*. 2024;73(3):44.
- Liu JF, et al. *JCO Precis Oncol*. 2024;8:e2300693.
- McDonald A, et al. *J Invest Dermatol*. 2025;145(2):323-333.
- O'Connell BC, et al. *J Immunother Cancer*. 2024;12(8):e009160.
- Ribas A, et al. *Cell*. 2017;170(6):1109-1119.e10.
- Xu-Monette ZY, et al. *Oncoimmunology*. 2024;13(1):2384667.